Dermal Fillers Boca Raton: What the FDA Approvals Actually Cover

The dermal fillers Boca Raton patients ask for by name — Juvéderm, Restylane, RHA — are among the most tightly regulated aesthetic treatments in the United States. Each is a Class III medical device that had to earn its own FDA approval, for a named facial area, on its own trial data. That record is public, and it is the most useful thing to read before a consultation, so this page is built from it.

Dermal fillers Boca Raton: which products are approved, and for where

Patients comparing dermal fillers in Boca Raton are usually choosing between clinics rather than between products, which is the wrong way round. Dermal fillers sit in the FDA’s most demanding device category. The agency’s own description is blunt about what that requires: a “Class III device”, “approved through the PMA process”, where “each device must demonstrate stand alone safety and effectiveness.” There is no borrowing credibility from a predecessor product. Every filler on the table below ran its own trial.

The approvals are also narrower than most marketing suggests. A product approved for nasolabial folds is not automatically approved for cheeks, and one approved for cheeks is not approved for the under-eye. Knowing which product carries which indication is the practical core of planning a treatment well.

Two things follow that are genuinely useful at a consultation. First, the under-eye now has four separately approved products, which is recent — that area was treated off-label for years. Second, SKINVIVE is approved for “intradermal injection to improve facial skin smoothness of the cheeks”, which is a skin quality treatment rather than a volumising one. They are different tools for different complaints, and picking between them is a clinical judgement rather than a menu choice.

How long results held in the trials that earned the approvals

Every duration figure published for a filler is a responder rate: the proportion of participants still showing at least a one-grade improvement on a defined scale, at a defined visit, judged by a blinded evaluator. It is not a measure of how long the gel is physically present. Reading it correctly is the difference between realistic expectations and disappointment at month nine.

Juvéderm Voluma XC has the longest published follow-up of the cheek products. Its pivotal trial randomised 282 participants and measured improvement on a six-point midface volume scale. At the primary endpoint, 85.6% of treated participants were responders against 38.9% of untreated controls. The durability curve is published in full, and it is unusually good:

Two-thirds of participants still meeting the responder definition two years after a cheek treatment is a strong result, and it is the reason midface work is often the best value on a filler menu. The fold products behave differently. Juvéderm Vollure XC, studied in the nasolabial folds, recorded 93.2% responders at month six and 59.4% at month eighteen. RHA 2 held above 80% at 64 weeks, with subject satisfaction above 86% at the same visit.

The practical reading: deep structural work in the cheek lasts longest, and fold correction sits closer to a year. Planning around that, rather than around a single advertised number, is what keeps a face looking consistent instead of cycling between full and flat.

The reversibility advantage, and where it stops

Hyaluronic acid’s real advantage over every other filler material is that it can usually be broken down. Hyaluronidase, an enzyme, dissolves HA gel, which means an HA result is adjustable in a way that most aesthetic treatments are not. If a lip is fuller than you wanted or a cheek sits slightly high, there is a route back. That is a genuine reason to prefer HA for anyone treating an area for the first time, and it is why it is the material used for the overwhelming majority of work here.

Hyaluronidase use for this purpose is off-label, meaning the enzyme is FDA-approved but not specifically for dissolving cosmetic filler. It usually works well. It is not instantaneous, it occasionally needs a second session, and it dissolves the body’s own hyaluronic acid alongside the product, so it is a tool to be used deliberately rather than casually. None of that changes the headline: an HA result can be adjusted, and that is a meaningful comfort for a first-time patient.

Where the real risk sits, and how to avoid it entirely

The FDA is direct about what actually goes wrong with fillers, and almost all of it traces to who is injecting and what they are injecting rather than to the products themselves. Its guidance to consumers is worth reading as a checklist for choosing a clinic.

On sourcing, the FDA says plainly: “Do not purchase dermal filler products online, because they could be counterfeit products or products that are not approved for use in the U.S.” On needle-free devices, the so-called hyaluron pens sold for home use, its October 2021 safety communication reported “serious injuries and in some cases, permanent harm to the skin, lips, or eyes” and stated that “FDA-approved dermal fillers are intended for prescription use only and for use with a syringe with a needle or cannula.” And on body contouring, the agency recommends against using fillers to increase breast or buttock size at all.

Its positive recommendation is a single line, and it is the one that matters: work with “a licensed health care provider who has experience in the fields of dermatology or plastic surgery.” Genuine product, a licensed clinical setting, and an experienced injector who knows facial vascular anatomy remove the great majority of the documented risk before a syringe is opened. That is the standard Brazelia MedSpa operates to, and it is a reasonable standard to hold any clinic to.

What patients actually experience in the first fortnight is far more ordinary: swelling, tenderness, small firm areas and bruising are common across every product’s trial data and settle within about two weeks. Knowing that in advance is usually the difference between a normal recovery and a worried phone call.

Frequently asked questions

Sources and how this page was built

Every product, approval date and indication on this page was read from the FDA premarket approval database on 26 September 2026, and every duration figure from the manufacturer’s Summary of Safety and Effectiveness Data filed with that approval. Where a figure is a responder rate, it is labelled as one and shown with its denominator. Where a widely repeated duration claim could not be traced to an approval document, it is not repeated here.

Why patients choose Brazelia MedSpa

This page is the best answer we can give. Most filler pages lead with a price per syringe and a promise of eighteen months. This one leads with the approval record, because that is what an experienced injector is actually working from, and a clinic willing to show you its reasoning in public is one that will explain its reasoning to you in the chair.

Injectable treatments at Brazelia MedSpa are performed by Khali Reed, CRNA, APRN, a master injector her patients know as the Facial Architect, in a practice under the medical direction of Dr. Herbert R. Slavin, MD. For filler work in Boca Raton in particular, that matters more than it does almost anywhere else in aesthetics: the difference between a good result and a problem is knowledge of where the vessels run.

Brazelia MedSpa has treated patients from the same address in downtown Boca Raton for 18 years, near Mizner Park, and serves patients across South Florida, from Delray Beach and Boynton Beach to Deerfield Beach and Fort Lauderdale. In a field where med spas open and close within a season, staying in one place that long is its own kind of evidence. Patients rate the practice 4.5 out of 5 across 24 Google reviews.

A face is also rarely treated as just a face here. Because Brazelia MedSpa runs hormone, metabolic, skin and regenerative programmes under one roof, a treatment plan can take account of what else is going on — skin quality, weight change, hormonal shifts — instead of being sold in isolation. Where that is relevant to you it comes up at the consultation. Where it is not, nobody raises it.

New patients start with a consultation, and nothing is treated on a first visit unless you want it to be. You will hear what the approved labelling actually supports before you hear what it costs.

This page describes what published labels, regulatory records and peer-reviewed research report about these treatments. It is general health information, not medical advice, and it is not a substitute for a consultation. Whether any treatment is appropriate for you is a clinical judgement that depends on your history and examination.